Medical devices for the treatment of eye diseases

Handbook of Experimental Pharmacology

Volumn 197, Issue , 2010, Pages 469-489

  Yasukawa, Tsutomu ^a   Ogura, Yuichiro ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NONE

Author keywords

Age related macular degeneration; Biodegradable polymer; Controlled release; Intraocular drug delivery system; Microsphere

Indexed keywords

ALPHA INTERFERON; BETAMETHASONE; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; ETHYLENE VINYL ACETATE COPOLYMER; FLUOCINOLONE ACETONIDE; FOSCARNET; GANCICLOVIR; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; MICROSPHERE; PEGAPTANIB; PHOTOSENSITIZING AGENT; POLYGLACTIN; POLYVINYL ALCOHOL; RANIBIZUMAB; STEROID; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; DRUG;

BIODEGRADABLE IMPLANT; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG MECHANISM; DRUG STABILITY; ENCAPSULATION; EYE DISEASE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; KIDNEY DYSFUNCTION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINITIS PIGMENTOSA; REVIEW; SUBRETINAL NEOVASCULARIZATION; SUSPENSION; UVEITIS; VITREORETINOPATHY; APPARATUS, EQUIPMENT AND SUPPLIES; DELAYED RELEASE FORMULATION; METHODOLOGY; PHARMACEUTICS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EQUIPMENT AND SUPPLIES; EYE DISEASES; HUMANS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77953248909     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-00477-3_16     Document Type: Review

References (63)

1. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111-118
2. Ambati J, Adamis AP (2002) Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res 21:145-151
3. American Academy of Ophthalmology (2000) Photodynamic therapy with verteporfin for agerelated macular degeneration. Ophthalmology 107:2314-2317
4. Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, Koch F (1998) Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 212:410-414
5. Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:14-22
6. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debré P, Leibowitch J (1997) Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 277:112-116
7. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007a) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182
8. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007b) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855-859
9. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002) Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: 3-year results of an open-label extension of 2 randomized clinical trials-TAP Report no. 5. Arch Ophthalmol 120:1307-1314
10. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444
11. Callanan DG (2007) Novel intravitreal fluocinolone acetonide implant in the treatment of chronic noninfectious posterior uveitis. Expert Rev Ophthalmol 2:33-44
12. Cantrill WH, Henry K, Melroe NH, Knobloch WH, Ramsay RC, Balfour HH (1989) Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 96:367-374
13. Chakravarthy U, Houston RF, Archer DB (1993) Treatment of age-related subfoveal neovascular membranes by teletherapy. Br J Ophthalmol 77:265-273
14. Cochereau-Massin I, Lehoang P, Lautier-Frau M, Zazoun L, Marcel P, Robinet M, Matheron S, Katlama C, Gharakhanian S, Rozenbaum W, et al. (1991) Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 98:1348-1355
15. Eckardt C, Eckardt U, Conrad HG (1999) Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 237:313-325
16. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ (2001) Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol 85:461-470
17. Geroski DH, Edelhauser HF (2001) Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 52:37-48
18. Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema. 2-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533-1538
19. Gonzalez-Avila G, Lozano D, Manjarrez ME, Ruiz VM, Terán L, Vadillo-Ortega F, Selman M (1995) Influence on collagen metabolism of vitreous from eyes with proliferative vitreoretinopathy. Ophthalmology 102:1400-1405
20. Gross JB, Bozzete SA, Mathews WC, Spector SA, Abramson IS, McCutchan JA, Mendez T, Munguia D, Freeman WR (1990) Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 97:681-686
21. Heinemann MH (1989) Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 107:1767-1772
22. Henderly DE, Freeman WR, Causey DM, Rao NA (1987) Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 94:425-434
23. Hinton DR, He S, Jin ML, Barron E, Ryan SJ (2002) Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 16:422-428
24. Holland GN, Sakamoto MJ, Hardy D, Sidikaro Y, Kreiger AE, Frenkel LM (1986) Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxyl-1- (hydroxy-methyl)ethoxymethyl] guanine. Arch Ophthalmol 104:1794-1800
25. Hueber A, Wiedemann P, Esser P, Heimann K (1996-1997) Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR). Int Ophthalmol 20:345-350
26. Ip M, Gorin MB (1996) Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. Am J Ophthalmol 122:594-595
27. Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, Gangnon RE, Puliafito CA (2004) Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 122:1131-1136
28. Jabs DA, Newman C, De Bustros S, Polk BF (1987) Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 94:824-830
29. Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P (2000) Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 107:2024-2033
30. Jerdan JA, Pepose JS, Michels RG, Hayashi H, de Bustros S, Sebag M, Glaser BM (1989) Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 96:801-810
31. Kaplan H (1996) Submacular surgery for choroidal neovascularization. Br J Ophthalmol 80:101 \
32. Kim SH, Galban CJ, Lutz RJ, Dedrick RL, Csaky KG, Lizak MJ, Wang NS, Tansey G, Robinson MR (2007) Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci 48:808-814
33. Klein R, Klein BEK, Linton KLP (1992) Prevalence of age-related maculopathy: the beaver dam eye study. Ophthalmology 99:933-943
34. Kunou N, Ogura Y, Yasukawa T, Kimura H, Miyamoto H, Honda Y, Ikada Y (2000) Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release 68:263-271
35. La Heij EC, van de Waarenburg MP, Blaauwgeers HG, Kessels AG, Liem AT, Theunissen C, Steinbusch H, Hendrikse F (2002) Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am J Ophthalmol 134:367-375
36. Lang LC (1995) Ocular drug delivery: conventional ocular formulations. Adv Drug Deliv Rev 16:39-43
37. Machemer R, Laqua H (1975) Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol 80:1-23
38. Macular Photocoagulation Study Group (1986) Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 104:503-512
39. Macular Photocoagulation Study Group (1990) Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 108:825-831
40. Macular Photocoagulation Study Group (1994a) Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112:480-488
41. Macular Photocoagulation Study Group (1994b) Laser photocoagulation for juxtafoveal choroidal neovascularization: 5-year results from randomized clinical trials. Arch Ophthalmol 112: 500-509
42. Maguire MG, Fine SL, Maguire AM, D'Amato RJ, Singerman LJ (2001) Results of the age-related macular degeneration and thalidomide study (AMDATS). Invest Ophthalmol Vis Sci 42:S233
43. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358:2240-2248
44. Maurice DM, Mishima S (1984) Ocular pharmacokinetics. In: Sears ML (ed) Pharmacology of the eye. Springer, New York
45. Milenkovic I, Weick M, Wiedemann P, Reichenbach A, Bringmann A (2003) P2Y receptormediated stimulation of Muller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation. Invest Ophthalmol Vis Sci 44:1211-1220
46. Mitchell SM, Membrey WL, Youle MS, Obi A, Worrell S, Gazzard BG (1999) Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol 83:652-655
47. Morley MG, Duker JS, Ashton P, Robinson MR (1995) Replacing ganciclovir implants. Ophthalmology 102:388-392
48. Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y (2003) Intraocular tissue distribution of betamethasone after intrascleral administration using a nonbiodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci 44:2702-2707
49. Pertile G, Glaes C (2002) Macular translocation with 360-degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol 134:560-565
50. Pharmacological Therapy for Macular Degeneration Study Group (1997) Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 115:865-872
51. Retinal Society Terminology Committee (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90:121-125
52. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431
53. Ryan SJ, Stout JT, Dugel PU (1994) Subretinal neovascularization. In: Ryan SJ (ed) Retina. Mosby, St. Louis
54. Sanborn GE, Anald R, Torti RE, Nightingale SD, Cal SX, Yates B, Ashton P, Smith T (1992) Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol 110:188-195
55. Scheiffarth OF, Kampik A, Gunther H, von der Mark K (1988) Proteins of the extracellular matrix in vitreoretinal membranes. Graefes Arch Clin Exp Ophthalmol 226:357-361
56. Smith TJ, Pearson PA, Blandford DL, Brown JD, Goins KA, Hollins JL, Schmeisser ET, Glavinos P, Baldwin LB, Ashton P (1992) Intravitreal sustained-release ganciclovir. Arch Ophthalmol 110:255-258
57. Tan DTH, Chee SP, Lim L, Lim ASM (1999) Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 106:223-231
58. Ussery FM, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ (1988) Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 95:640-648
59. Vrabec TR, Baldassano VF, Whitcup SM (1998) Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4 + counts. Ophthalmology 105:1259-1264
60. Yasukawa T, Kimura H, Kunou N, Miyamoto H, Honda Y, Ogura Y, Ikada Y (2000) Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch Clin Exp Ophthalmol 238:186-190
61. Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y (2006) Drug delivery from ocular implants. Expert Opin Drug Deliv 3:261-273
62. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y (2004) Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 23:253-281
63. Yasukawa T, Tabata Y, Kimura H, Kunou N, Ogura Y (2007) Development of drug-delivery systems to the posterior segments of the eye. Expert Rev Ophthalmol 2:197-211